Join to View Full Profile
1 Penn PlzSuite 3508New York, NY 10119
Phone+1 212-845-8208
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. David Guyer, MD is a board certified ophthalmologist in New York, New York. He is currently licensed to practice medicine in New York, Florida, and California.
Education & Training
Johns Hopkins UniversityResidency, Ophthalmology, 1987 - 1990
MetroWest Medical CenterInternship, Transitional Year, 1986 - 1987- Johns Hopkins University School of MedicineClass of 1986
Certifications & Licensure
CA State Medical License 1990 - Present
NY State Medical License 1987 - 2025
FL State Medical License 1996 - 2000
American Board of Ophthalmology Ophthalmology
Publications & Presentations
PubMed
- 1 citationsDigital indocyanine green videoangiography and choroidal neovascularization. 1992.Lawrence A Yannuzzi, Jason S Slakter, John A Sorenson, David R Guyer, Dennis A Orlock
Retina. 2012-02-01 - 9 citationsPegaptanib sodium for macular edema secondary to central retinal vein occlusion.John J Wroblewski, John A Wells 3rd, Anthony P Adamis, Ronald R Buggage, Emmett T Cunningham Jr
Archives of Ophthalmology. 2009-04-01 - 77 citationsPegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.Lawrence J. Singerman, Harvey Masonson, Manju Patel, Anthony P. Adamis, Ronald Buggage
The British Journal of Ophthalmology. 2008-12-01
Press Mentions
Merck and EyeBio Begin Phase 2b/3 Trial for Restoret in DMEOctober 2nd, 2024- Merck, EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret for Diabetic Macular EdemaSeptember 8th, 2024
Eleusis Announces the Appointment of David Guyer, M.D., to Board of DirectorsSeptember 23rd, 2019- Join now to see all
